復旦張江(01349.HK)附屬斥6億人幣建醫藥生產基地二期
復旦張江(01349.HK)公布,公司之附屬泰州復旦張江作為集團重要的生產基地,為滿足集團後續研發項目的產業化進程及推進現有研發管線申報進度,根據集團戰略規劃和經營發展需要,董事會批准泰州復旦張江在其現有廠房之相鄰土地上進行二期醫藥生產基地項目建設。
項目包括建設總建築面積約4.2萬平方米的抗體偶聯藥物車間、固體製劑車間、注射劑車間以及與之配套的辦公、研發、質檢、倉儲、環保等輔助設施。該項目投資總額為6億元人民幣,資金來源全部為自有資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.